Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection
- PMID: 18295551
- DOI: 10.1016/j.meegid.2008.01.004
Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection
Abstract
Recent research implicates viral infection as a factor that may contribute to the risk of prostate cancer. Allelic variation at the RNASEL locus is associated with the risk of infection by a newly discovered retrovirus called XMRV, and with hereditary risk of prostate cancer. This evidence suggests that the RNASEL locus has undergone antagonistic coevolution with the retrovirus over evolutionary time. If this is the case, then both the RNASEL locus and the retrovirus should show evidence of positive selection. Here we use molecular-evolutionary methods to investigate the prediction that the RNASEL locus will exhibit evidence of positive selection. We find evidence that positive selection has acted on this locus over evolutionary time. We further find, using a Bayesian estimation procedure, that Asp541Glu, which was found to be associated with prostate cancer risk in Caucasians in a recent meta-analysis, shows an elevated probability of positive selection. Previous studies provide evidence for rapid evolution of the infection-mediating gag gene in the XMRV retrovirus. Taken together, these results suggest that antagonistic coevolution may have occurred between a specific host locus involved in immune defense (RNASEL) and a viral pathogen. In turn, genetic variation associated with this apparent coevolution may influence susceptibility to prostate cancer.
Similar articles
-
Positive selection on the gene RNASEL: correlation between patterns of evolution and function.Mol Biol Evol. 2012 Oct;29(10):3161-8. doi: 10.1093/molbev/mss123. Epub 2012 Apr 17. Mol Biol Evol. 2012. PMID: 22513284
-
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.Clin Cancer Res. 2004 Nov 1;10(21):7150-6. doi: 10.1158/1078-0432.CCR-04-0982. Clin Cancer Res. 2004. PMID: 15534086
-
Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.Genes Chromosomes Cancer. 2004 Feb;39(2):119-25. doi: 10.1002/gcc.10308. Genes Chromosomes Cancer. 2004. PMID: 14695991
-
Inflammation, infection, and prostate cancer.Curr Opin Urol. 2008 May;18(3):315-9. doi: 10.1097/MOU.0b013e3282f9b3b7. Curr Opin Urol. 2008. PMID: 18382242 Review.
-
Involvement of the RNAse L gene in prostate cancer.Bull Soc Sci Med Grand Duche Luxemb. 2006;(1):21-8. Bull Soc Sci Med Grand Duche Luxemb. 2006. PMID: 16869093 Review.
Cited by
-
RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.Mol Biol Rep. 2011 Nov;38(8):5099-105. doi: 10.1007/s11033-010-0657-2. Epub 2011 Jan 9. Mol Biol Rep. 2011. PMID: 21221811
-
Evidence from 40 Studies that 2 Common Single-Nucleotide Polymorphisms (SNPs) of RNASEL Gene Affect Prostate Cancer Susceptibility: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Compliant Meta-Analysis.Med Sci Monit. 2019 Nov 5;25:8315-8325. doi: 10.12659/MSM.917715. Med Sci Monit. 2019. PMID: 31686670 Free PMC article.
-
A history of recurrent positive selection at the toll-like receptor 5 in primates.Mol Biol Evol. 2009 Apr;26(4):937-49. doi: 10.1093/molbev/msp018. Epub 2009 Jan 29. Mol Biol Evol. 2009. PMID: 19179655 Free PMC article.
-
Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.Prostate. 2010 Nov 1;70(15):1716-27. doi: 10.1002/pros.21207. Prostate. 2010. PMID: 20564318 Free PMC article.
-
Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells.J Virol. 2010 Jul;84(13):6288-96. doi: 10.1128/JVI.00274-10. Epub 2010 Apr 21. J Virol. 2010. PMID: 20410264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
